AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
IceCure Medical shares surge 10.08% premarket after FDA authorizes ProSense® cryoablation for low-risk breast cancer in women aged 70+.
ByAinvest
Tuesday, Nov 18, 2025 8:46 am ET1min read
IceCure Medical Ltd. (ICCM) surged 10.08% in premarket trading following the announcement that its ProSense® Cryoablation System received regulatory approval in Switzerland for treating breast, lung, liver, and kidney cancers. This approval expands the system’s commercial potential in Europe, reinforcing the company’s recent momentum from prior milestones, including FDA authorization for breast cancer treatment in women aged 70 and above. The news aligns with IceCure’s strategy to broaden access to its minimally invasive cryoablation technology, potentially driving revenue growth and market share in oncology. Other recent updates, such as a COO promotion and upcoming Q3 earnings, were not material to the premarket rally.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet